Ligelizumab, a high-affinity IgG1kappa humanized anti-IgE monoclonal antibody was shown to be very potent in IgE binding to the FcεRI, but failed to significantly improve asthma control and exacerbation rates in severe asthma, possibly because of its faster clearance as compared to omalizumab [183]. The gene discussed is IGHE; the disease is asthma.